Our communities participated in the research, yet we are still waiting for Gilead to determine how much we receive
At a moment when science has delivered what may be the most powerful HIV prevention tool in a generation, South Africa finds itself caught between breakthrough and bottleneck. Lenacapavir, a twice-yearly injection offering near-complete protection, is being formally launched by President Ramaphosa in Mpumalanga — yet civil society groups warn that the doses allocated by its maker, Gilead Sciences, are so few as to render the rollout more symbolic than transformative. The country that bore the trials, hosted the clinics, and carries the world's heaviest HIV burden now waits at the back of a supply line it helped build. What medicine has made possible, commerce has made scarce.
- South Africa is launching a drug that could end its HIV epidemic — but fewer than 975,000 doses have been allocated over two years, against a modeled need of 2 million annually, leaving a gap that researchers describe not as a shortfall but as a chasm.
- Only 38,000 doses had arrived by April, delayed by post-importation testing requirements that Gilead has not sought to waive, turning a historic rollout into a slow trickle.
- Civil society groups — the Treatment Action Campaign, the Health Justice Initiative, and the African Alliance — are pressing President Ramaphosa directly, calling the rollout unambitious and warning that narrow population targets will leave most of the 8 million South Africans living with HIV untouched.
- Gilead has softened some licensing terms through the Medicines Patent Pool, theoretically opening a path for local generic production, but domestic manufacturing capacity remains limited and the company's grip on supply volumes stays firm.
- Health Minister Motsoaledi has announced a three-province rollout prioritizing highest-risk groups and spoken of eliminating HIV by 2030 — a vision that, advocates say, cannot be realized without access that does not yet exist.
South Africa is preparing to launch lenacapavir, a twice-yearly injection that offers near-complete protection against HIV — and almost immediately, the country is confronting a wall of scarcity. President Cyril Ramaphosa and Health Minister Aaron Motsoaledi are set to formally introduce the drug in Secunda, Mpumalanga, in what should be a moment of triumph. Instead, civil society organizations are urging the president to press Gilead Sciences hard, warning that the company's allocations are so limited that the rollout risks becoming performance rather than public health.
The numbers are stark. South Africa is receiving fewer than 975,000 doses over two years — and by April, only 38,000 had arrived, slowed further by regulatory testing requirements. Researchers at Wits University's HE2RO group estimate that roughly 2 million people would need to take the drug annually to materially slow new infections and end the epidemic by 2034. The gap is not a rounding error.
The bitterness runs deep. South Africa carries the world's heaviest HIV burden — 8 million people living with the virus, 170,000 new infections each year. The country was the first in Africa to approve lenacapavir. Its communities participated in the clinical trials. Its scientists helped generate the proof that the drug works. And yet, as advocates have noted, the company that owns the formula still controls how much of it South Africa receives and when.
The Treatment Action Campaign, the Health Justice Initiative, and the African Alliance have been pointed in their criticism — calling the rollout unambitious, the population targets too narrow, and Gilead's supply volumes minuscule. They have also faulted the company for not seeking relief from post-importation testing requirements and for moving slowly on enabling local generic production.
Gilead has made some movement, recently easing licensing conditions through the Medicines Patent Pool to allow South African manufacturers to apply for voluntary licenses. But local pharmaceutical capacity is constrained, and Gilead's control over supply remains effectively absolute. Motsoaledi has announced a rollout beginning in three provinces, prioritizing adolescent girls, sex workers, men who have sex with men, people who inject drugs, and transgender people. He has spoken of eliminating HIV as a public health threat by 2030. That vision, for now, outpaces the supply chain that would make it real.
South Africa is about to launch a drug that could change everything about its fight against HIV—and almost immediately, the country is running into a wall of scarcity.
Lenacapavir, a twice-yearly injection made by Gilead Sciences, offers something close to complete protection against HIV infection. President Cyril Ramaphosa and Health Minister Aaron Motsoaledi are scheduled to formally introduce it in Secunda, Mpumalanga, on Friday. The moment should feel triumphant. Instead, civil society organizations are urging the president to lean hard on Gilead, warning that the company has allocated so little of the drug to South Africa that the rollout risks becoming theater rather than medicine.
The numbers tell the story. South Africa is receiving fewer than 975,000 doses over the next two years. By April, only 38,000 had arrived, delayed further by regulatory testing requirements. But researchers at Wits University's HE2RO group have modeled what would actually move the needle: about 2 million people in South Africa would need to take lenacapavir annually to materially slow new HIV infections and bring the pandemic to an end by 2034. The gap between what's coming and what's needed is not a shortfall. It is a chasm.
The context makes the shortage feel especially bitter. South Africa carries the world's heaviest HIV burden—8 million people living with the virus, 170,000 new infections each year. The country was the first in Africa to approve lenacapavir. South African communities participated in the clinical trials. South African clinics hosted the research. South African scientists helped generate the data that proved the drug works. And yet, as Tian Johnson of the African Alliance put it, the company that owns the formula still controls how much of it South Africa receives, when it arrives, and how fast access can expand.
The Treatment Action Campaign, the Health Justice Initiative, and the African Alliance have been blunt in their criticism. They say the rollout plan is unambitious and small-scale, that the population targets are too narrow, and that Gilead's supply volumes are minuscule. They have also criticized the company for not seeking an exemption from South Africa's post-importation testing requirements—a regulatory hurdle that has already delayed the program—and for moving slowly to enable local pharmaceutical manufacturers to produce generic versions of the drug.
Gilead has made some concessions. The company recently softened its licensing conditions through the Medicines Patent Pool, opening a pathway for South African pharmaceutical companies to apply for voluntary licenses to manufacture lenacapavir using imported active pharmaceutical ingredients. But the bottleneck remains real. Local capacity is limited. Gilead's control over supply is absolute.
Motsoaledi told parliament this week that the rollout will begin in three provinces and will prioritize people at highest risk: adolescent girls and women under 25, sex workers, men who have sex with men, people who inject drugs, and transgender people. He also offered an optimistic framing, suggesting that South Africa could eliminate HIV as a public health threat by 2030 if the country works hard enough. But that vision depends on access that, for now, simply does not exist. The drug is here. The need is immense. The supply is not.
Citações Notáveis
We must ask why we are being asked to celebrate when South Africa's rollout plan is unambitious, low-scale and in danger of being more about the pomp than the public health impact— Coalition of civil society organizations including Treatment Action Campaign, Health Justice Initiative, and African Alliance
Our communities participated in the research, our clinics hosted the trials, and our scientists helped produce the data. Yet we are still waiting for Gilead to determine how much of the product we receive— Tian Johnson, African Alliance
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that South Africa was first to approve this drug if the supply is so constrained?
Because it signals something about power. South Africa proved it could move fast on regulation, but that speed doesn't translate into access. The approval was a win on paper. The supply shortage is the real story.
Is Gilead deliberately restricting supply, or is this a manufacturing capacity problem?
The source doesn't say Gilead is deliberately restricting—it's more that the company controls the terms. They set the volumes, they set the licensing conditions. Whether that's strategy or constraint, the effect is the same: South Africa gets less than a quarter of what modeling suggests it needs.
What does the generic manufacturing pathway actually change?
It opens a door, but a narrow one. Local companies can now apply for licenses to make the drug using imported ingredients. That's better than before. But it doesn't solve the immediate problem, and it still leaves Gilead holding the keys to the active ingredient itself.
The health minister sounds optimistic about 2030. Is that realistic?
Only if supply changes dramatically. His timeline depends on reaching 2 million people annually. Current allocations suggest reaching maybe a tenth of that. The optimism and the reality are not aligned.
What's the human cost of waiting?
170,000 new infections a year in a country where a prevention tool now exists but is not available to most people who need it. That's the gap between what could be and what is.